Renal
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the renal testing capabilities of Mayo Clinic Laboratories, including:
- Glomerular disease
- Kidney function
- Renal genetics
- Renal pathology
- Urinary stone services
News and updates
The latest
John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of whether patients are actually absorbing their medications or whether a new approach might be needed.
There have been concerns in the U.S. recently about the possible harmful side effects from absorbing gadolinium-based contrast agents into the body during some MRI exams. To address some of the anxiety and concerns over this issue, Paul Jannetto, Ph.D., DABCC, FAACC, and Joshua Bornhorst, Ph.D., DABCC, FAACC, Co-Directors of the Mayo Clinic Metals Laboratory and leading experts in this field, have compiled the following list of the most up-to-date information.
A team of Mayo Clinic pathologists have discovered a new tissue biomarker, DNAJB9, for fibrillary glomerulonephritis, a rare kidney disease of unknown pathogenesis and poor outlook—nearly half of all patients end up on dialysis within four years of diagnosis.